CD274 and cancer: Cancer immunotherapies, involving stimulation of innate and adaptive immune responses crucial to antitumor immunity, are mainly based on immune checkpoint inhibitors (ICIs), such as antiprogrammed cell death protein 1 (PD-1) and antiprogrammed death-ligand 1 (PD-L1) antibodies, cell-based therapies like engineered chimeric antigen receptor T cells (CAR-T), and cancer vaccines [193].